search
Back to results

Safety and Efficacy of NBO in Acute Intracerebral Hemorrhage

Primary Purpose

Normobaric Oxygen, Cerebral Hemorrhage

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Normobaric Oxygen
Sponsored by
Capital Medical University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Normobaric Oxygen focused on measuring Cerebral Hemorrhage, Normobaric oxygen therapy, Mask oxygen, edema

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patient Age ≥ 18 and ≤ 80 years;
  2. The diagnosis of ICH is confirmed by brain CT scan;
  3. NIHSS score ≥ 6 and GCS > 8 upon presentation;
  4. Functional independence prior to ICH, defined as pre-ICH mRS ≤ 1
  5. Signed and dated informed consent is obtained.

Exclusion Criteria:

  1. Known history of severe chronic obstructive pulmonary disease (Forced Expiratory Vital Capacity less than 1.0L or oxygen dependent).
  2. New York Heart Association Class III heart failure.
  3. Patient will undergo surgical evacuation of ICH .
  4. Inability to undergo neuroimaging with MRI .
  5. GCS <8
  6. Baseline mRS ≥ 2
  7. Intraparenchymal hematoma secondary to rupture of cerebral aneurysm or bleeding of arteriovenous (A-V) malformation or cerebral tumors
  8. Any condition which, in the judgment of the investigator, might increase the risk to the patient.

Sites / Locations

  • Xuanwu Hospital, Captial Medical University

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Experimental: NBO group

Control group

Arm Description

For eligible patients into the group of cerebral hemorrhage,Low-flow oxygen is delivered through the facemask at a rate of 8 L/min, once a hour, every 4 hours. Regular treatment is based on associated guidelines for ICH .

Low-flow oxygen is delivered through the facemask at a rate of 2 L/min, once a hour, every 4 hours. Regular treatment is based on associated guidelines for ICH .

Outcomes

Primary Outcome Measures

The proportion of death or major disability

Secondary Outcome Measures

The change in the midline shift from the initial to follow-up CT/MRI scans
The change in the volume of ICH from the initial to follow-up CT/MRI scans
The change of cerebral blood flow in perihematomal lesions follow-up CTP scans
The evaluation of neurological impairment caused by a stroke
National Institute of Health stroke scale(NIHSS),The score ranges from 0 to 42. The higher the score, the more severe the nerve damage.
Neurological function outcome
The modified Rankin scale is used to measure the recovery of neurological function in patients after stroke. The score range is from 0 to 5. The higher the score, the worse the neurological function is restored. We need to calculate the proportion of the modified Rankin scale 0-2.
The evaluation of serum biomarkers
We used ELISA kits to detect the lebvels of neuron - specific enolase (NSE) , matrix metalloprotease 9 (MMP-9), reactive oxygen species (ROS) and hypoxia-inducing factor 1a (HIF-1a) in blood. The results were measured in ng/ml.

Full Information

First Posted
October 22, 2019
Last Updated
October 29, 2019
Sponsor
Capital Medical University
search

1. Study Identification

Unique Protocol Identification Number
NCT04144868
Brief Title
Safety and Efficacy of NBO in Acute Intracerebral Hemorrhage
Official Title
Safety and Efficacy of NBO in Acute Intracerebral Hemorrhage
Study Type
Interventional

2. Study Status

Record Verification Date
October 2019
Overall Recruitment Status
Unknown status
Study Start Date
October 30, 2019 (Anticipated)
Primary Completion Date
August 8, 2020 (Anticipated)
Study Completion Date
December 30, 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Capital Medical University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Intracerebral hemorrhage (ICH) is one of the most devastating nontraumatic cerebral vascular diseases. Its exacerbation is often related to a mass effect because of hematoma formation and edema in the perihematoma, which plays a key role in disease deterioration. Perihematoma edema is an important contributor to brain injuries secondary to ICH and one of the risk factors that leads to disease deterioration and high mortality. Brain edema following ICH was believed to be induced by the breakdown of the blood-brain barrier and ischemia and hypoxia of the perihematoma. Normobaric oxygen (NBO) therapy is a treatment that delivers high-flow oxygen at normobaric pressure through a facemask to supplement the oxygen supply,which maintain the oxygen concentration of typically 40-100% ,can increase the arterial oxygen content, and alleviate tissue hypoxia. NBO therapy has been shown to provide neuroprotection against ischemic stroke in an experimental study and a clinical trial. To the best of our knowledge, the potential of NBO therapy for neuroprotection against human hemorrhagic stroke has not been investigated. There are two studies about NBO interventions in the rat model of intracerebral hemorrhage.The one showed NBO did not worsen hemorrhage severity or brain edema. There were no significant differences in hemorrhagic blood volumes or brain water content. NBO did not affect any of the neurological outcome tests in the primary or secondary studies. Another one showed NBO groups improved NSSs,decreased contents of brain water, HIF-1α and VEGF, and fewer apoptotic cells in the perihematoma at 72 h after ICH compared with the ICH control group. These results suggest that NBO therapy with oxygen delivered at 90% conferred best neuroprotection to ICH rats, potentially through amelioration of brain edema by suppressing HIF-1α and VEGF expression in the perihematoma. But there is no clinical study on the safety and efficacy of NBO in patients with intracerebral hemorrhage.NBO has the advantages of simple operation, non-invasiveness and early application, which makes it have great application prospects in the treatment of ICH.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Normobaric Oxygen, Cerebral Hemorrhage
Keywords
Cerebral Hemorrhage, Normobaric oxygen therapy, Mask oxygen, edema

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
High-flow oxygen is delivered through the facemask at a rate of 8 L/min, once a hour, every 4 hours to the ICH patient.
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Experimental: NBO group
Arm Type
Experimental
Arm Description
For eligible patients into the group of cerebral hemorrhage,Low-flow oxygen is delivered through the facemask at a rate of 8 L/min, once a hour, every 4 hours. Regular treatment is based on associated guidelines for ICH .
Arm Title
Control group
Arm Type
No Intervention
Arm Description
Low-flow oxygen is delivered through the facemask at a rate of 2 L/min, once a hour, every 4 hours. Regular treatment is based on associated guidelines for ICH .
Intervention Type
Other
Intervention Name(s)
Normobaric Oxygen
Primary Outcome Measure Information:
Title
The proportion of death or major disability
Time Frame
90 days after the onset
Secondary Outcome Measure Information:
Title
The change in the midline shift from the initial to follow-up CT/MRI scans
Time Frame
Day0, Day1,Day3,Day7,Day14
Title
The change in the volume of ICH from the initial to follow-up CT/MRI scans
Time Frame
Day0, Day1,Day3,Day7,Day14
Title
The change of cerebral blood flow in perihematomal lesions follow-up CTP scans
Time Frame
Day0, Day1,Day7
Title
The evaluation of neurological impairment caused by a stroke
Description
National Institute of Health stroke scale(NIHSS),The score ranges from 0 to 42. The higher the score, the more severe the nerve damage.
Time Frame
Day0, Day1,Day3,Day7,Day90
Title
Neurological function outcome
Description
The modified Rankin scale is used to measure the recovery of neurological function in patients after stroke. The score range is from 0 to 5. The higher the score, the worse the neurological function is restored. We need to calculate the proportion of the modified Rankin scale 0-2.
Time Frame
Day90
Title
The evaluation of serum biomarkers
Description
We used ELISA kits to detect the lebvels of neuron - specific enolase (NSE) , matrix metalloprotease 9 (MMP-9), reactive oxygen species (ROS) and hypoxia-inducing factor 1a (HIF-1a) in blood. The results were measured in ng/ml.
Time Frame
Day0, Day1,Day3,Day7,Day14

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient Age ≥ 18 and ≤ 80 years; The diagnosis of ICH is confirmed by brain CT scan; NIHSS score ≥ 6 and GCS > 8 upon presentation; Functional independence prior to ICH, defined as pre-ICH mRS ≤ 1 Signed and dated informed consent is obtained. Exclusion Criteria: Known history of severe chronic obstructive pulmonary disease (Forced Expiratory Vital Capacity less than 1.0L or oxygen dependent). New York Heart Association Class III heart failure. Patient will undergo surgical evacuation of ICH . Inability to undergo neuroimaging with MRI . GCS <8 Baseline mRS ≥ 2 Intraparenchymal hematoma secondary to rupture of cerebral aneurysm or bleeding of arteriovenous (A-V) malformation or cerebral tumors Any condition which, in the judgment of the investigator, might increase the risk to the patient.
Facility Information:
Facility Name
Xuanwu Hospital, Captial Medical University
City
Beijing
ZIP/Postal Code
100053
Country
China

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
25700288
Citation
McCourt R, Gould B, Kate M, Asdaghi N, Kosior JC, Coutts S, Hill MD, Demchuk A, Jeerakathil T, Emery D, Butcher KS. Blood-brain barrier compromise does not predict perihematoma edema growth in intracerebral hemorrhage. Stroke. 2015 Apr;46(4):954-60. doi: 10.1161/STROKEAHA.114.007544. Epub 2015 Feb 19.
Results Reference
background
PubMed Identifier
29600891
Citation
Ding J, Zhou D, Sui M, Meng R, Chandra A, Han J, Ding Y, Ji X. The effect of normobaric oxygen in patients with acute stroke: a systematic review and meta-analysis. Neurol Res. 2018 Jun;40(6):433-444. doi: 10.1080/01616412.2018.1454091. Epub 2018 Mar 30.
Results Reference
background
PubMed Identifier
26820681
Citation
Cai L, Stevenson J, Geng X, Peng C, Ji X, Xin R, Rastogi R, Sy C, Rafols JA, Ding Y. Combining Normobaric Oxygen with Ethanol or Hypothermia Prevents Brain Damage from Thromboembolic Stroke via PKC-Akt-NOX Modulation. Mol Neurobiol. 2017 Mar;54(2):1263-1277. doi: 10.1007/s12035-016-9695-7. Epub 2016 Jan 28.
Results Reference
background
PubMed Identifier
29408705
Citation
Xu Q, Fan SB, Wan YL, Liu XL, Wang L. The potential long-term neurological improvement of early hyperbaric oxygen therapy on hemorrhagic stroke in the diabetics. Diabetes Res Clin Pract. 2018 Apr;138:75-80. doi: 10.1016/j.diabres.2018.01.017. Epub 2018 Feb 3.
Results Reference
background
PubMed Identifier
27867482
Citation
Shi SH, Qi ZF, Luo YM, Ji XM, Liu KJ. Normobaric oxygen treatment in acute ischemic stroke: a clinical perspective. Med Gas Res. 2016 Oct 14;6(3):147-153. doi: 10.4103/2045-9912.191360. eCollection 2016 Jul-Sep.
Results Reference
background
PubMed Identifier
25804925
Citation
Liang J, Qi Z, Liu W, Wang P, Shi W, Dong W, Ji X, Luo Y, Liu KJ. Normobaric hyperoxia slows blood-brain barrier damage and expands the therapeutic time window for tissue-type plasminogen activator treatment in cerebral ischemia. Stroke. 2015 May;46(5):1344-1351. doi: 10.1161/STROKEAHA.114.008599. Epub 2015 Mar 24.
Results Reference
background
PubMed Identifier
21415401
Citation
Fujiwara N, Mandeville ET, Geng X, Luo Y, Arai K, Wang X, Ji X, Singhal AB, Lo EH. Effect of normobaric oxygen therapy in a rat model of intracerebral hemorrhage. Stroke. 2011 May;42(5):1469-72. doi: 10.1161/STROKEAHA.110.593350. Epub 2011 Mar 17.
Results Reference
background
PubMed Identifier
26872098
Citation
You P, Lin M, Li K, Ye X, Zheng J. Normobaric oxygen therapy inhibits HIF-1alpha and VEGF expression in perihematoma and reduces neurological function defects. Neuroreport. 2016 Mar 23;27(5):329-36. doi: 10.1097/WNR.0000000000000542.
Results Reference
background
PubMed Identifier
28580533
Citation
Xu H, Li R, Duan Y, Wang J, Liu S, Zhang Y, He W, Qin X, Cao G, Yang Y, Zhuge Q, Yang J, Chen W. Quantitative assessment on blood-brain barrier permeability of acute spontaneous intracerebral hemorrhage in basal ganglia: a CT perfusion study. Neuroradiology. 2017 Jul;59(7):677-684. doi: 10.1007/s00234-017-1852-9. Epub 2017 Jun 3.
Results Reference
result
PubMed Identifier
33499916
Citation
Chen Z, Ding J, Wu X, Bao B, Cao X, Wu X, Yin X, Meng R. Safety and efficacy of normobaric oxygenation on rescuing acute intracerebral hemorrhage-mediated brain damage-a protocol of randomized controlled trial. Trials. 2021 Jan 26;22(1):93. doi: 10.1186/s13063-021-05048-4.
Results Reference
derived

Learn more about this trial

Safety and Efficacy of NBO in Acute Intracerebral Hemorrhage

We'll reach out to this number within 24 hrs